173 related articles for article (PubMed ID: 20336586)
21. [Insulin resistance].
Arteaga Llona A
Rev Med Chil; 1993 Feb; 121(2):197-8. PubMed ID: 8303118
[TBL] [Abstract][Full Text] [Related]
22. [Lipid metabolism and insulin resistance--clinical aspects and pathobiochemistry].
Gries FA; Hübinger A
Wien Klin Wochenschr; 1994; 106(24):763-7. PubMed ID: 7846895
[TBL] [Abstract][Full Text] [Related]
23. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
24. TNF-alpha and obesity.
Tzanavari T; Giannogonas P; Karalis KP
Curr Dir Autoimmun; 2010; 11():145-56. PubMed ID: 20173393
[TBL] [Abstract][Full Text] [Related]
25. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
[TBL] [Abstract][Full Text] [Related]
26. The role of adiponectin in obesity, diabetes, and cardiovascular disease.
Kawano J; Arora R
J Cardiometab Syndr; 2009; 4(1):44-9. PubMed ID: 19245516
[TBL] [Abstract][Full Text] [Related]
27. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Schernthaner GH; Schernthaner G
Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
[TBL] [Abstract][Full Text] [Related]
28. The current biology of resistin.
Steppan CM; Lazar MA
J Intern Med; 2004 Apr; 255(4):439-47. PubMed ID: 15049878
[TBL] [Abstract][Full Text] [Related]
29. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
30. Thermodynamics, liposuction, and metabolism.
Kelley DE
N Engl J Med; 2004 Jun; 350(25):2542-4. PubMed ID: 15201408
[No Abstract] [Full Text] [Related]
31. Apelin, a promising target for type 2 diabetes treatment?
Castan-Laurell I; Dray C; Knauf C; Kunduzova O; Valet P
Trends Endocrinol Metab; 2012 May; 23(5):234-41. PubMed ID: 22445464
[TBL] [Abstract][Full Text] [Related]
32. Fatty acid receptors as new therapeutic targets for diabetes.
Rayasam GV; Tulasi VK; Davis JA; Bansal VS
Expert Opin Ther Targets; 2007 May; 11(5):661-71. PubMed ID: 17465724
[TBL] [Abstract][Full Text] [Related]
33. Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases?
Tsai S; Clemente-Casares X; Revelo XS; Winer S; Winer DA
Diabetes; 2015 Jun; 64(6):1886-97. PubMed ID: 25999531
[TBL] [Abstract][Full Text] [Related]
34. Orphan nuclear receptors and the regulation of nutrient metabolism: understanding obesity.
Pearen MA; Muscat GE
Physiology (Bethesda); 2012 Jun; 27(3):156-66. PubMed ID: 22689791
[TBL] [Abstract][Full Text] [Related]
35. Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseases.
Talukdar S; Olefsky JM; Osborn O
Trends Pharmacol Sci; 2011 Sep; 32(9):543-50. PubMed ID: 21663979
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?
Timmers S; Hesselink MK; Schrauwen P
Ann N Y Acad Sci; 2013 Jul; 1290():83-9. PubMed ID: 23855469
[TBL] [Abstract][Full Text] [Related]
37. [Intestinal microbiota, obesity and insulin resistance].
Pernet A; Petriccioli N
Rev Med Suisse; 2011 Nov; 7(317):2236-8. PubMed ID: 22400352
[TBL] [Abstract][Full Text] [Related]
38. G protein-coupled receptors as targets for anti-diabetic therapeutics.
Oh DY; Olefsky JM
Nat Rev Drug Discov; 2016 Mar; 15(3):161-72. PubMed ID: 26822831
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes mellitus as a disorder of galanin resistance.
Fang P; Shi M; Zhu Y; Bo P; Zhang Z
Exp Gerontol; 2016 Jan; 73():72-7. PubMed ID: 26585047
[TBL] [Abstract][Full Text] [Related]
40. GPR43/FFA2: physiopathological relevance and therapeutic prospects.
Bindels LB; Dewulf EM; Delzenne NM
Trends Pharmacol Sci; 2013 Apr; 34(4):226-32. PubMed ID: 23489932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
